Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Broder

Showing results (401-410 of 451) with videos related to

Pageof 46
Sort By:
Lancet (London, England)|September 21, 1985
Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivoS Broder, R Yarchoan, J M Collins, et al.
Journal of Medicinal Chemistry|March 1, 1990
Acid-stable 2'-fluoro purine dideoxynucleosides as active agents against HIVV E Marquez, C K Tseng, H Mitsuya, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine|August 27, 2016
Shared Decision Making to Improve the Emergency Care of Older Adults: A Research AgendaTeresita M Hogan, Natalie L Richmond, Christopher R Carpenter, et al.
Hepatology (Baltimore, Md.)|October 1, 1992
A pilot study of 2',3'-dideoxyinosine for the treatment of chronic hepatitis BM W Fried, J C Korenman, A M Di Bisceglie, et al.
Science (New York, N.Y.)|July 28, 1989
In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosineR Yarchoan, H Mitsuya, R V Thomas, et al.
The Journal of Infectious Diseases|October 1, 1993
A pilot study of sequential therapy with zidovudine plus acyclovir, dideoxyinosine, and dideoxycytidine in patients with severe human immunodeficiency virus infectionB Y Nguyen, L E Shay, K M Wyvill, et al.
Arthritis and Rheumatism|June 3, 2008
Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapyE Keystone, G R Burmester, R Furie, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 1, 1987
The disposition and metabolism of 2',3'-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeysJ A Kelley, C L Litterst, J S Roth, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 1, 1986
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptaseP A Furman, J A Fyfe, M H St Clair, et al.
Journal of the Neurological Sciences|July 4, 2024
Development and validation of a claims-based algorithm to identify patients with Neuromyelitis Optica Spectrum disorderAnisha M Patel, Alex Exuzides, Irina Yermilov, et al.
Pageof 46

Showing results (401-410 of 451) with videos related to

Sort By:
Pageof 46
Lancet (London, England)|September 21, 1985
Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivoS Broder, R Yarchoan, J M Collins, et al.
Journal of Medicinal Chemistry|March 1, 1990
Acid-stable 2'-fluoro purine dideoxynucleosides as active agents against HIVV E Marquez, C K Tseng, H Mitsuya, et al.
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine|August 27, 2016
Shared Decision Making to Improve the Emergency Care of Older Adults: A Research AgendaTeresita M Hogan, Natalie L Richmond, Christopher R Carpenter, et al.
Hepatology (Baltimore, Md.)|October 1, 1992
A pilot study of 2',3'-dideoxyinosine for the treatment of chronic hepatitis BM W Fried, J C Korenman, A M Di Bisceglie, et al.
Science (New York, N.Y.)|July 28, 1989
In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosineR Yarchoan, H Mitsuya, R V Thomas, et al.
The Journal of Infectious Diseases|October 1, 1993
A pilot study of sequential therapy with zidovudine plus acyclovir, dideoxyinosine, and dideoxycytidine in patients with severe human immunodeficiency virus infectionB Y Nguyen, L E Shay, K M Wyvill, et al.
Arthritis and Rheumatism|June 3, 2008
Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapyE Keystone, G R Burmester, R Furie, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 1, 1987
The disposition and metabolism of 2',3'-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeysJ A Kelley, C L Litterst, J S Roth, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 1, 1986
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptaseP A Furman, J A Fyfe, M H St Clair, et al.
Journal of the Neurological Sciences|July 4, 2024
Development and validation of a claims-based algorithm to identify patients with Neuromyelitis Optica Spectrum disorderAnisha M Patel, Alex Exuzides, Irina Yermilov, et al.
Pageof 46